Sigma Pharmaceutical : Change of Director's Interest Notice

Appendix 3Y Change of Director's Interest Notice Appendix 3Y Change of Director's Interest Notice

Rule 3.19A.2

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity SIGMA PHARMACEUTICALS LIMITED

ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Robert Hooper
Date of last notice	23/01/2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	23/01/2017
No. of securities held prior to change	33,657,388 Ordinary Shares 4,926,539 Shares allocated pursuant to the employee share plan 33,612 Shares allocated pursuant to the loan funded long term incentive plan 28,459,560 Short term incentive plan performance rights 237,677
Class	Ordinary

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director's Interest Notice

Number acquired	3,784,034
Number disposed
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$1,522,533.12
No. of securities held after change	33,657,388 Ordinary Shares 8,710,573 Shares allocated pursuant to the employee share plan 33,612 Shares allocated pursuant to the loan funded long term incentive plan 24,675,526 Short term incentive plan performance rights 237,677
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	3,784,034 shares have been released following receipt of loan repayment under long term incentive plan

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired

+ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Interest disposed

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation

Interest after change

Part 3 - +Closed period Appendix 3Y Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3